Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension
H Izzedine, O Rixe, B Billemont, A Baumelou… - American Journal of …, 2007 - Elsevier
Angiogenesis inhibitors that target the epidermal growth factor (EGF) receptor (EGFR) and
vascular endothelial growth factor (VEGF) constitute an important addition to the therapeutic …
vascular endothelial growth factor (VEGF) constitute an important addition to the therapeutic …
Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma
G Sonpavde, TE Hutson… - Expert opinion on …, 2008 - Taylor & Francis
Background: The recent approvals of sunitinib, sorafenib and temsirolimus have
revolutionized the management of renal cell carcinoma (RCC). Pazopanib (GW-786034) is a …
revolutionized the management of renal cell carcinoma (RCC). Pazopanib (GW-786034) is a …
[HTML][HTML] Rapid vascular regrowth in tumors after reversal of VEGF inhibition
MR Mancuso, R Davis, SM Norberg… - The Journal of …, 2006 - Am Soc Clin Investig
Inhibitors of VEGF signaling can block angiogenesis and reduce tumor vascularity, but little
is known about the reversibility of these changes after treatment ends. In the present study …
is known about the reversibility of these changes after treatment ends. In the present study …
Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of …
T Inai, M Mancuso, H Hashizume, F Baffert… - The American journal of …, 2004 - Elsevier
Angiogenesis inhibitors are receiving increased attention as cancer therapeutics, but little is
known of the cellular effects of these inhibitors on tumor vessels. We sought to determine …
known of the cellular effects of these inhibitors on tumor vessels. We sought to determine …
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results
Purpose We studied the safety, clinical activity, and pharmacokinetics (PK) of AG-013736,
an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet …
an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet …
Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling
F Baffert, T Le, B Sennino, G Thurston… - American Journal …, 2006 - journals.physiology.org
The vasculature of the embryo requires vascular endothelial growth factor (VEGF) during
development, but most adult blood vessels lose VEGF dependence. However, some …
development, but most adult blood vessels lose VEGF dependence. However, some …
AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast …
LJ Wilmes, MG Pallavicini, LM Fleming, J Gibbs… - Magnetic resonance …, 2007 - Elsevier
Dynamic contrast-enhanced MRI (DCE-MRI) was used to noninvasively evaluate the effects
of AG-03736, a novel inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine …
of AG-03736, a novel inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine …
Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer
HS Rugo, AT Stopeck, AA Joy, S Chan… - Journal of clinical …, 2011 - ascopubs.org
Purpose This multicenter, randomized, double-blind, phase II study assessed safety and
efficacy of axitinib plus docetaxel in metastatic breast cancer (MBC). Patients and Methods …
efficacy of axitinib plus docetaxel in metastatic breast cancer (MBC). Patients and Methods …
Chemotherapy agents and hypertension: a focus on angiogenesis blockade
M Jain, RR Townsend - Current hypertension reports, 2007 - Springer
Two observations highlight the importance of this review. The first observation is that high
blood pressure is the most frequent comorbid condition in cancer registries which directly …
blood pressure is the most frequent comorbid condition in cancer registries which directly …
Axitinib for renal cell carcinoma
Background: The approval of sunitinib, sorafenib and temsirolimus has dramatically altered
the management of renal cell carcinoma (RCC). Bevacizumab plus IFN may also be added …
the management of renal cell carcinoma (RCC). Bevacizumab plus IFN may also be added …